KaloBios Pharmaceuticals (NASDAQ:KBIO) is a biopharmaceutical company based in San Francisco, CA, focused on the development of monoclonal antibody therapeutics.
KaloBios's business strategy involves in-licensing antibodies, typically from academic institutions, and developing Humaneered™ antibody versions through clinical proof-of-concept studies. The company aims to out-license these technologies to big pharmaceutical/biotechnology companies for further clinical development and commercialization of the products. Alongside this strategy, KaloBios intends to retain the rights for specific antibodies targeted at specialty or orphan indications.
We are starting our initiation of coverage with a target price of $10.1, which reflects an upside of 47% on the stock's IPO price with the following highlights:
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|